AMGN Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 21.23% compared to Amgen's net margin of 23.32%. Amgen's return on equity of 97.08% beat Johnson & Johnson's return on equity of 30.18%.

Amgen has a consensus price target of $313.56, signalling upside risk potential of 4.86%. On the other hand Johnson & Johnson has an analysts' consensus of $170.92 which suggests that it could grow by 3.36%. Given that Amgen has higher upside potential than Johnson & Johnson, analysts believe Amgen is more attractive than Johnson & Johnson.

Amgen has a beta of 0.491, which suggesting that the stock is 50.876% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.579%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.1%. Johnson & Johnson offers a yield of 3.05% to investors and pays a quarterly dividend of $1.30 per share. Amgen pays 118.14% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

Amgen quarterly revenues are $8.1B, which are smaller than Johnson & Johnson quarterly revenues of $23.7B. Amgen's net income of $1.7B is lower than Johnson & Johnson's net income of $5.5B. Notably, Amgen's price-to-earnings ratio is 27.28x while Johnson & Johnson's PE ratio is 17.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.74x versus 4.41x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 21.23% compared to Amgen's net margin of 21.68%. Amgen's return on equity of 97.08% beat Eli Lilly and's return on equity of 78.25%.

Amgen has a consensus price target of $313.56, signalling upside risk potential of 4.86%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.57%. Given that Eli Lilly and has higher upside potential than Amgen, analysts believe Eli Lilly and is more attractive than Amgen.

Amgen has a beta of 0.491, which suggesting that the stock is 50.876% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.1%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Amgen pays 118.14% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

Amgen quarterly revenues are $8.1B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Amgen's net income of $1.7B is lower than Eli Lilly and's net income of $2.8B. Notably, Amgen's price-to-earnings ratio is 27.28x while Eli Lilly and's PE ratio is 64.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.74x versus 14.56x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 21.23% compared to Amgen's net margin of -907.48%. Amgen's return on equity of 97.08% beat Moderna's return on equity of -29.23%.

Amgen has a consensus price target of $313.56, signalling upside risk potential of 4.86%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 48.44%. Given that Moderna has higher upside potential than Amgen, analysts believe Moderna is more attractive than Amgen.

Amgen has a beta of 0.491, which suggesting that the stock is 50.876% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.1%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amgen pays 118.14% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Amgen quarterly revenues are $8.1B, which are larger than Moderna quarterly revenues of $107M. Amgen's net income of $1.7B is higher than Moderna's net income of -$971M. Notably, Amgen's price-to-earnings ratio is 27.28x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.74x versus 3.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 21.23% compared to Amgen's net margin of 26.7%. Amgen's return on equity of 97.08% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Amgen has a consensus price target of $313.56, signalling upside risk potential of 4.86%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 32.96%. Given that Regeneron Pharmaceuticals has higher upside potential than Amgen, analysts believe Regeneron Pharmaceuticals is more attractive than Amgen.

Amgen has a beta of 0.491, which suggesting that the stock is 50.876% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.1%. Regeneron Pharmaceuticals offers a yield of 0.32% to investors and pays a quarterly dividend of $0.88 per share. Amgen pays 118.14% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Amgen quarterly revenues are $8.1B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3B. Amgen's net income of $1.7B is higher than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Amgen's price-to-earnings ratio is 27.28x while Regeneron Pharmaceuticals's PE ratio is 13.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.74x versus 4.44x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.